|Bid||11.75 x 800|
|Ask||12.45 x 3200|
|Day's Range||12.22 - 12.70|
|52 Week Range||8.27 - 17.62|
|Beta (3Y Monthly)||1.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.70|
Amicus Therapeutics (FOLD) today announced the election and appointment of Burke W. Whitman to its Board of Directors, effective at the end of this quarter. Mr. Whitman is a proven leader of corporate and military organizations. He has served as a corporate CEO, CFO and board member of multiple publicly-traded and Fortune 500 healthcare service companies, as well as the commanding general of the 4th Marine Division and the commander of Marine Forces Reserve. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “On behalf of our Board of Directors, I am pleased to announce Burke Whitman’s appointment to the Amicus Board.
CRANBURY, N.J., May 10, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside.
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25.81% and -9.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Cranbury, New Jersey-based company said it had a loss of 56 cents per share. Losses, adjusted for non-recurring costs, came to 39 cents per share. The results fell short of Wall Street expectations. ...
1Q19 Galafold® (migalastat) Strong Launch Trends Continue with Largest Quarterly Number of Net New Patients Added Globally (150+ Net New Galafold Patients in 1Q19) 1Q19.
Catalyst Pharma (CPRX) is expected to announce revenue results on its lead product, Firdapse, when it releases first-quarter 2019 earnings performance.
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's a roundup of top developments in the biotech space over the last 24 hours. Stock In Focus G1 Therapeutics Plans Regulatory Submission For Bone Marrow Preservation Drug G1 Therapeutics Inc (NASDAQ: ...
Amicus Therapeutics (FOLD) today announced initial preclinical data from its investigational adeno-associated viral (AAV) gene therapy program for Pompe disease in mice. Pompe disease is an inherited lysosomal storage disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA).
CRANBURY, N.J., April 25, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 8,.
CRANBURY, N.J., April 15, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced the company will present initial preclinical data from its investigational adeno-associated.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a small-cap stock with a market capitalization of US$3.1b. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a k...
Amicus Therapeutics, Inc. (NASDAQ: FOLD ) has an extensive portfolio of novel therapies for rare diseases with a focus on lysosomal storage disorders, according to Janney Montgomery Scott. The Analyst ...
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Amicus Therapeutics (FOLD) today announced that the United States Patent and Trademark Office has issued two new patents directed to the composition of matter and methods of making ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly mannose-6 phosphate (M6P), to enhance uptake. ATB200 is the biologic component of the Company’s investigational Pompe treatment paradigm AT-GAA, which consists of ATB200 co-administered with AT2221, a pharmacological chaperone.
came up Wednesday night in the "Lightning Round" of Jim Cramer's entertaining and informative Mad Money program. Cramer said, "I think this one is really good. On-Balance-Volume (OBV) line turned stronger in late December.
The latest earnings announcement Amicus Therapeutics, Inc. (NASDAQ:FOLD) released in December 2018 confirmed that losses became smaller relative to the prior year's level as a result of recent tailwinds BelowRead More...